Optimal anticoagulation duration of unfractionated and low molecular weight heparin in non-ST elevation acute coronary syndrome: A systematic review of the literature

Impact of Early Invasive Approach on Outcomes of Patients With Acute Coronary Syndrome and Baseline Anemia: Analysis From the ACSIS Registry

“…Even though there was no association between the use of low molecular weight heparin and major bleeding by multivariable analysis, occurrence of nuisance bleeding is known to have negative impact on prognosis after ACS, especially in patients treated with PCI . Prolonged duration of anticoagulation has been also shown to increase bleeding without significant improvement in cardiovascular outcomes . The best treatments for ACS patients with baseline anemia are not known.…”

“…39 Prolonged duration of anticoagulation has been also shown to increase bleeding without significant improvement in cardiovascular outcomes. 40 The best treatments for ACS patients with baseline anemia are not known. Expedited, efficient, and safe methods to define etiology of anemia should be applied to treat the underlying condition and to eliminate or to reduce the risk of bleeding.…”

Pharmacology of Heparin and Related Drugs

“…However, UH is often preferred because its effects are more readily reversed. A lack of data exists to suggest the optimal duration of anticoagulation in non-STEMI, with longer durations tending to present an increased risk of bleeding without clear improvements in outcome (Riaz et al, 2014). …”

Anticoagulants and Primary PCI

“…Data suggests that extending the anticoagulation with post procedure UFH or LMWH does not reduce ischemic complications but does increase bleeding risks [11,12]. Therefore barring some compelling indication (very high thrombus burden or left ventricular thrombus) UFH or LMWH should not be continued after primary PCI.…”